MedTrace Logo

Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction

NCT01372930 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2011-06-14

No results posted yet for this study

Summary

Our aim is to observe whether anti-TNF-alpha regimen will effect serum adiponectin concentration after myocardial infarction/reperfusion and also beneficial for the patients undergoing percutaneous coronary intervention (PCI).

Conditions

Interventions

DRUG

Etanercept

Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI

DRUG

saline

saline 1ml(subcutaneous injection) at 2h and 72h after PCI

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2014-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01372930 on ClinicalTrials.gov